Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) is one of the most extensively studied and utilized viral vectors in clinical gene transfer research. However, the serum instability and immunogenicity of AAV vectors significantly limit their application. Here, we endeavored to overcome these limitations by developing a straightforward approach for site-specific PEGylation of AAV via genetic code expansion. This technique includes incorporation of the azide moiety into the AAV capsid protein followed by orthogonal and stoichiometric conjugation of a variety of polyethylene glycols (PEGs) through click chemistry. Using this approach, only the chosen site(s) was consistently PEGylated under mild conditions, preventing nonselective conjugation. Upon a series of in vitro examinations, AAVs conjugated with 20-kD PEG at sites Q325+1, S452+1, and R585+1 showed a 1.7- to 2.4-fold stability improvement in pooled human serum and a nearly twofold reduction in antibody recognition. Subsequent animal research on Sprague Dawley rats displayed a promising 20% reduction in antibody inducement and a higher virus titer in the blood. Together, our data demonstrate successful protection of an AAV vector from antibody neutralization and blood clearance, thereby increasing the efficiency of therapeutic gene delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, another study using the PEGylation at UAA site strategy encountered the issue of decreased titer as well, although antibody recognition was modestly improved (140).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×
“PEGylation is a well-established technique for improving the pharmacokinetics and pharmacodynamics of protein pharmaceuticals [25] and has been widely investigated in viral vector protection, including in adenovirus production [26,27].”
MethodExpanding the Genetic Code of Escherichia coli
Wang, L., Brock, A., Herberich, B., & Schultz, P. G. (2001) · Science · doi:10.1126/science.1060077 · Cited by 1,499 · cited 1×
“In this study, we used a straightforward and precise strategy of genetic code expansion [30,31] for PEGylation of recombinant AAV-2 vectors.”
MethodBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“Given that most people have already been exposed to AAV and consequently have antibodies against AAV [13,14,16], the clinical application of AAV vectors is greatly restricted.”
BackgroundAn Expanded Eukaryotic Genetic Code
Chin, J. W., Cropp, T. A., Anderson, J. C., Mukherji, M., Zhang, Z., & Schultz, P. G. (2003) · Science · doi:10.1126/science.1084772 · Cited by 820
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 3×
“Given that most people have already been exposed to AAV and consequently have antibodies against AAV [13,14,16], the clinical application of AAV vectors is greatly restricted.”
BackgroundMethodThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“This determination was based on previous studies of AAV capsid protein modification and the crystal structure of AAV [35], taking the steric hindrance of NAEK insertion into consideration.”
MethodWu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390 · cited 1×
“These sites were chosen after considering their tolerance, location, and potential functions, which were selected to avoid involvement in host cell recognition, receptor binding, or host–virus membrane fusion [33].”
BackgroundPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358 · cited 1×
“Moreover, even quite low levels of antibodies can prevent successful transduction [17].”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
Site-specific PEGylation of proteins containing unnatural amino acids
Deiters, A., Cropp, T. A., Summerer, D., Mukherji, M., & Schultz, P. G. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.059 · Cited by 262 · cited 1×
“In this study, we used a straightforward and precise strategy of genetic code expansion [30,31] for PEGylation of recombinant AAV-2 vectors.”
Method
Research works printed but not linked: 2
- Fields, B., Knipe, D., Howley, P., and Griffin, D. (2007). Fields Virology, Lippincott Williams & Wilkins. [5th ed.].
- Muzyczka, 2001, Parvoviridae: The viruses and their replication, Fields Virol., 2, 2327
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“A study used PEG-N-hydroxysuccinimide with an electro-philic succinimidyl propionic acid functional group to cross-link with lysine residues on rAAV2 capsid to enable NAb evasion.”
BackgroundAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans
Shen, Y., Campbell, R. E., Côté, D. C., & Paquet, M.-È. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.00041 · Cited by 120
“Alternatively, as regions of the AAV capsid important for antibody binding have been identified, inserting mutations in these residues could abolish epitope recognition (Kotterman and Schaffer, 2014), or the AAV could be pegylated to shield the virus capsid from the immune system (Yao et al., 2017).”
BackgroundUsing genetically incorporated unnatural amino acids to control protein functions in mammalian cells
Nödling, A. R., Spear, L. A., Williams, T., Luk, L. Y. P., & Tsai, Y.-H. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180042 · Cited by 71
Evading and overcoming AAV neutralization in gene therapy
Earley, J., Piletska, E. V., Ronzitti, G., & Piletsky, S. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.11.006 · Cited by 93
Therapeutic applications of genetic code expansion
Huang, Y., & Liu, T. (2018) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2018.09.003 · Cited by 68
“Apart from hGH, site-specific PEGylation using genetic code expansion has also been expanded to the optimization of IFN-α2b [92], fibroblast growth factor 21 (FGF21) [93] as well as AAV vectors [94].”
MethodBecker, J., Fakhiri, J., & Grimm, D. (2022) · Pathogens · doi:10.3390/pathogens11070756 · Cited by 79
“To this end, a multitude of chemical and biochemical approaches exist to couple oligonucleotides [128], sugar moie‐ ties [129–131], proteins [132], or synthetic polymers such as polyethylene glycol [133,134] to the AAV capsid.”
BackgroundAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Is Viral Vector Gene Delivery More Effective Using Biomaterials?
Wang, Y., Bruggeman, K. F., Franks, S. J., Gautam, V., Hodgetts, S. I., Harvey, A. R., Williams, R. J., & Nisbet, D. R. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001238 · Cited by 79
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Similarly, another study using the PEGylation at UAA site strategy encountered the issue of decreased titer as well, although antibody recognition was modestly improved (140).”
ResultMaterials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 59
Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation
Seo, J. W., Ingham, E. S., Mahakian, L. M., Tumbale, S. K., Wu, B., Aghevlian, S., Shams, S., Baikoghli, M., Jain, P., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15818-4 · Cited by 46
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Lam, A. K., Zhang, J., Frabutt, D. A., Mulcrone, P. L., Li, L., Zeng, L., Herzog, R. W., & Xiao, W. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.008 · Cited by 42
Puzzo, F., Zhang, C., Gray, B. P., Zhang, F., Sullenger, B. A., & Kay, M. A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.007 · Cited by 42
“Biorthogonal copper-free click chemistry(28) for AAV conjugation has been successfully exploited to label the capsid with fluorophores in order to track the vector in live cells,(47) and different chemical moieties have been utilized in an attempt to shield the vector from anti-AAV antibodies.(48)”
MethodSelf-citationArtificial Intelligence‐Based Approaches for AAV Vector Engineering
Tan, F., Dong, Y., Qi, J., Yu, W., & Chai, R. (2025) · Advanced Science · doi:10.1002/advs.202411062 · Cited by 42
Genetic-Based Approaches to Inherited Metabolic Liver Diseases
Zabaleta, N., Hommel, M., Salas, D., & González‐Aseguinolaza, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.140 · Cited by 36
“Chemical modification of the AAV surface, such as PEG-coating, 200 can be used to avoid detection by the immune system; however, excessive coating may also result in obscuring interaction with receptors required for infection.”
Zhou, X., Liu, J., Xiao, S., Liang, X., Li, Y., Mo, F., Xin, X., Yang, Y., & Gao, C. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s459905 · Cited by 34
“136 In addition to PEGylation to protect against neutralization, the use of a targeting peptide or protein incorporation strategy can improve or alter the tropism of AAV capsids.”
BackgroundSelf-citationRNA-Guided Adenosine Deaminases: Advances and Challenges for Therapeutic RNA Editing
Chen, G., Katrekar, D., & Mali, P. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00046 · Cited by 29
Lam, A. K., Frabutt, D. A., Li, L., & Xiao, W. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.124 · Cited by 28
Zhang, C., Zhou, X., Yao, T., Tian, Z., & Zhou, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700374 · Cited by 25
Self-citationChemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 26
“109 The resulting viruses exhibited an approximately 50% reduction in anti-AAV antibody generation upon intravenous administration.”
BackgroundRevolution of AAV in Drug Discovery: From Delivery System to Clinical Application
Yin, L., He, H., Zhang, H., Shang, Y., Fu, C., Wu, S., & Jin, T. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70447 · Cited by 26
“The surface tethering strategies, such as polyethylene glycol tethering (PEGylation), utilize chemical modifications to evade NAbs or achieve tissue targeting, which affect cell interaction and internalization as well as tissue accumulation and retention [88].”
Synthesis at the interface of virology and genetic code expansion
Kelemen, R. E., Erickson, S. B., & Chatterjee, A. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.07.015 · Cited by 20
Honda, Y., Nagao, S., Kinoh, H., Liu, X., Matsudaira, N., Dirisala, A., Nitta-Matsutomo, S., Nomoto, T., Hayashita‐Kinoh, H., Miura, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c11085 · Cited by 19
Insidious Insights: Implications of viral vector engineering for pathogen enhancement
Sandbrink, J. B., Alley, E. C., Watson, M. C., Koblentz, G. D., & Esvelt, K. M. (2022) · Gene Therapy · doi:10.1038/s41434-021-00312-3 · Cited by 22
“Non-genetic modifications of capsids and envelope glycoproteins – for instance, the shielding of surface antigens through PEGylation or with other synthetic polymers [28] or the use of lipid bilayer envelopes to shield vectors from antibody neutralization [29]—are not passed onto viral progeny and may hence represent…”
BackgroundWang, S., & Xiao, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052213 · Cited by 20
Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice
Chang, H., Du, A., Jiang, J., Ren, L., Liu, N., Zhou, X., Liang, J., Gao, G., & Wang, D. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101129 · Cited by 14
“13,22,23,25 As a result, an additional puri fi cation step following click reaction is necessary to remove unconjugated ligand, increasing the complexity and cost associated with vector manufacturing.”
BackgroundSelf-citationZhang, Y., Chen, Z., Wang, X., Yan, R., Bao, H., Chu, X., Guo, L., Wang, X., Li, Y., Mu, Y., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.07.023 · Cited by 13
Self-citationChemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
Mulcrone, P. L., Lam, A. K., Frabutt, D. A., Zhang, J., Chrzanowski, M., Herzog, R. W., & Xiao, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-35547-0 · Cited by 15
Structural characterization of an envelope-associated adeno-associated virus type 2 capsid
Hull, J. A., Mietzsch, M., Chipman, P. R., Strugatsky, D., & McKENNA, R. V. (2021) · Virology · doi:10.1016/j.virol.2021.09.010 · Cited by 13
Hao, R.-Z., Ma, K., Ru, Y., Li, D., Song, G.-Y., Lu, B.-Z., Liu, H.-N., Li, Y., Zhang, J., Wu, C., et al. (2021) · RNA Biology · doi:10.1080/15476286.2021.1907055 · Cited by 12
Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies
Ma, Y., & Shen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664968 · Cited by 15
“Polyethylene glycol (PEG) modi fi cation of AAV vectors can reduce immune recognition, extending their circulation time in the body (109).”
Delivering CRISPR to the HIV-1 reservoirs
Gurrola, T. E., Effah, S. N., Sariyer, I. K., Dampier, W., Nonnemacher, M. R., & Wigdahl, B. L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1393974 · Cited by 12
“While the same can be said of viral vectors (Yao et al., 2017; Thadani et al., 2020), it is more difficult and infrequent.”
BackgroundTowards Physiologically and Tightly Regulated Vectored Antibody Therapies
Page, A., Fusil, F., & Cosset, F. (2020) · Cancers · doi:10.3390/cancers12040962 · Cited by 12
Biopolymers augment viral vectors based gene delivery
Balakrishnan, B., & David, E. (2019) · Journal of Biosciences · doi:10.1007/s12038-019-9905-3 · Cited by 12
Pan, T. S., Yang, C.-H., Zhao, K., Sun, Y.-L., Rao, Z., Qu, W., Zhang, S., Jin, X., Yu, Y., & Zhang, X. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100143 · Cited by 10
Matsudaira, N., Honda, Y., Kinoh, H., Liu, X., Nagao, S., Nitta-Matsutomo, S., Guo, H., Hayashita‐Kinoh, H., Aizawa, M., Muguruma, K., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114477 · Cited by 5
Gene and cell-based therapies for retinal and optic nerve disease
Esposito, E. P., Han, I. C., & Johnson, T. V. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00016-2 · Cited by 5
Gene therapy shines light on congenital stationary night blindness for future cures
Zhang, Y., Lin, S., Yu, L., Lin, X. Y., Qu, S., Ye, Q., Yu, M., Chen, W., & Wu, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06392-8 · Cited by 5
“Additionally, strategies such as chemical modifications [163, 164], shell induction [165], and directed evolution or rational design to construct less immunogenic AAV capsids may reduce immune responses, though these approaches may require further development before clinical application.”
Biteghe, F. A. N., Mungra, N., Malindi, Z., Chalomie, N. E. T., Stanislas, K. A., Yasmin‐Karim, S., Makrigiorgos, G. M., Chipidza, F., Akinrinmade, O. A., Sridhar, S., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71255 · Cited by 4
“…to induce an immune response), reduced antigenicity (recognizability by antibodies generated due to an immunogenic response), reduced toxicity, masking of non-specific recognition sites, and resistance to proteolytic degradation and anti-drug antibodies (due to reduced accessibility) [230, 231].”
Zheng, Z., Wang, Y., Wu, X., Zhang, H., Chen, H., Lin, H., Shen, Y., & Xia, Q. (2023) · Vaccines · doi:10.3390/vaccines11101606 · Cited by 4
“Beyond the control of their replication, viral phenotypes can be simultaneously modified by the versatile side chain of UAA to jointly produce several desirable properties, such as improved cell tropisms and manufacturability [40,41].”
BackgroundLiu, Y., Liang, F., Zhang, R., Tang, C., Li, X., Wang, Y., He, Z., & Liu, H. (2025) · Materials Horizons · doi:10.1039/d5mh00203f · Cited by 4
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Zhu, S., Zhang, J., Jiang, X., Peng, C., Liu, H., & Qian, F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115773 · Cited by 3
Advances in endothelial cell targeting by AAV vectors
Cichoń, M., Jozkowicz, A., & Grochot‐Przeczek, A. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15740 · Cited by 5
“Therefore, PEG-based approaches require highly standardized production protocols and stringent quality-control measures (Yao et al., 2017; Pinto et al., 2025).”
Milagros, S., de Erenchun, P. R.-R., Guembe, M., Carte, B., Méndez, M., Uribarri, A., & Aldabe, R. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00430-7 · Cited by 4
“Furthermore, site-specific pegylation and oligo conjugations have been employed to engineer viral shielding, providing protection to AAV particles against neutralizing antibodies [26, 28].”
BackgroundMethodInfluentialAn Expanded Toolbox for Versatile Chemical Editing of Adeno‐Associated Virus
Pham, Q. T., Glicksman, J., Han, B., Koo, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202516157 · Cited by 2
Hebbelstrup, A. S., & Teilum, K. (2024) · ChemistrySelect · doi:10.1002/slct.202402826 · Cited by 2
Knapman, F. L., Cohen, E. M., Kulaga, T., Lovell, N. H., Lisowski, L., Burke, P. G. R., & Bilston, L. E. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101559 · Cited by 2
Adeno-associated viruses escort nanomaterials to specific cells and tissuesPreprint
Nagao, K., Paniagua, E. V., Lei, K., Beckham, J. L., Worthington, P., Manthey, M., Ye, M., Koehler, F., Kim, Y. J., Malkin, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647267 · Cited by 2
“Although AAV capsids, which are ~20 nm self-assembled protein nanoparticles, have been previously functionalized with small molecules 40–44 , polymers 45,46 , and multichelators 47 , their direct conjugation to another nanoparticle species remained to be demonstrated.”
Kim, J., Jeong, K. J., Kim, G., & Choi, J. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2407.07033 · Cited by 1
“For instance, ncAAs have been incorporated into therapeutic proteins such as adeno-associated viruses, human growth hormone, and interferons [21, 23, 24].”
MethodXiao, Y., Honda, Y., Matsudaira, N., Kinoh, H., Shen, X., Haochen, G., Hayashita-Kinoh, H., Gao, S., Awaad, A., Miura, Y., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114844 · Cited by 2
Delivery platforms for in vivo CAR-T engineering
Wang, H., Qiao, G., Ma, M., Zhao, H., Luo, L., & Liu, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1841160 · Cited by 2
“Safety enhancements for AAV include reducing pre-existing neutralizing antibody (NAb) interference — capsid glycosylation or PEGylation masks antigenic epitopes, improving vector bioavailability in patients with high NAb titers (50 – 53).”
Wang, K., Zheng, M., Askew, C., Zhang, X., Li, C., & Han, Z. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200128 · Cited by 3
Non-canonical capsid engineering highlights new possibilities for AAV vectorology
Zhang, Z., & Counsell, J. R. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101221 · Cited by 1
Therapeutic applications of genetic code expansion
Huang, Y., Wang, Y., Hu, L., Qin, X., & Liu, T. (2018) · Scientia Sinica Chimica · doi:10.1360/n032018-00071 · Cited by 1
Chemical modification strategies of viral vectors for gene therapy
Zhang, C., & Zhou, D. (2018) · Scientia Sinica Chimica · doi:10.1360/n032018-00075
Self-citationFadhilah, F. R., Riyadi, S. A., & Yuliani, E. (2022) · Nusantara Science and Technology Proceedings · doi:10.11594/nstp.2022.2204
“The World Health Organization (WHO) recommends adding ethylene glycol as a preservative in pooled sera because of the antifreeze and antibacterial properties of ethylene glycol (Yao et al., 2017).”
BackgroundZhang, Y., Shi, Y., Zhou, X., Han, X., Wang, F., Zhang, J., Luo, J., Wang, X., Wang, Y., Ji, D., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01166
Self-citationAn Expanded Toolbox for Versatile Chemical Editing of Adeno‐Associated Virus
Pham, Q. T., Glicksman, J., Han, B., Koo, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2026) · Angewandte Chemie · doi:10.1002/ange.202516157
Guo, S., Xu, X., Li, G., Yang, Y., Yan, Z., Wang, X., Jing, P., Zhou, Y., Jia, M., Wang, Y., et al. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag072
“…uptake in vivo , resulting in prolonged circulation and facilitating their optimal utilization of the enhanced permeability and retention (EPR) effects for achieving specific and high accumulation in tumors [36–38]; and (iii) PEGylation can reduce the immunogenicity of the DDSs [39, 40].”
Recombinant Adeno‐Associated Viral Therapeutics and Gene Doping. How to Detect It?
Mesonzhnik, N. V., Afonin, M., Novikova, P. M., & Postnikov, P. V. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70121
Site‐Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids
Sarkar, R., Joshi, M., & Chatterjee, A. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.1922738
Site‐Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids
Sarkar, R., Joshi, M., & Chatterjee, A. (2026) · Angewandte Chemie · doi:10.1002/ange.1922738
Metadata
- Authors
- Yao, T., Zhou, X., Zhang, C., Yu, X., Tian, Z., Zhang, L., & Zhou, D.
- Affiliations
- Peking University (CN)
- Corresponding author
- Zhang, Chuanling
- Zhou, Demin
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2017-07-11
- Volume
- 22
- Issue
- 7
- Pages
- 1155
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6152081
- OpenAlex
- W2735631314
- Cited by
- 68
- References
- 35
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 11 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81530090, 81673342, 81361168002, 2016YFA0501500)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- adeno-associated virus, site-specific PEGylation, genetic code expansion, click chemistry, serum stability, immunogenicity, antibody neutralization, gene therapy vectors, blood clearance
- MeSH terms
- Dependovirus, Animals, Antibody Formation, Binding Sites, Cell Line, Genetic Vectors, Humans, Immunity, Active, Male, Mutation, Polyethylene Glycols, Surface Properties, Rats, Sprague-Dawley, Gene Transfer Techniques, Capsid Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.